Product Description: Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP)[1].
Applications: Cancer-Kinase/protease
Formula: C24H30N6O3S
References: [1]Su WG, et al. Preparation of pyridopyrazine derivatives for use as Syk inhibitors. WO2012167733 A1./[2]Na Yang, et al. HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo. Blood (2016) 128 (22): 3970.
CAS Number: 1415792-84-5
Molecular Weight: 482.60
Compound Purity: 99.94
Research Area: Cancer
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Syk